
# Differential diagnosis for primary TMAs: atypical HUS, TTP, and STEC-HUS<sup>1-5</sup>



\*Shiga-toxin/EHEC test is warranted in history/presence of GI symptoms.

The information on this page is intended as educational information for healthcare providers. It does not replace a healthcare professional's judgment or clinical diagnosis.

# The catastrophic consequences of atypical HUS make RAPID DIAGNOSIS and CLINICAL INTERVENTION CRITICAL<sup>4</sup>

## Atypical HUS can cause SUDDEN and PROGRESSIVE damage<sup>3</sup>

- 33% to 40% of all patients die or progress to ESRD with the first clinical manifestation
- 65% of all atypical HUS patients die, require dialysis, or have permanent renal damage within the first year after diagnosis despite PE/PI

## Atypical HUS is a CHRONIC, LIFE-THREATENING condition

- The complement system is always "on" and regulated by natural inhibitors<sup>5</sup>
- Genetic mutations in complement inhibitors result in chronic, uncontrolled complement activation<sup>5</sup>
- Complement-mediated TMA persists despite PE/PI, dialysis<sup>4</sup>, or kidney transplantation<sup>6</sup>, and results in extra-renal morbidities

#### Atypical HUS has SYSTEMIC impact

- TMA occurs throughout the body and affects multiple vital organs, including the renal, nervous, and cardiovascular systems<sup>4</sup>
- 63% of atypical HUS patients have at least 1 complication outside of the kidney, including neurological, cardiovascular, and gastrointestinal systems<sup>3</sup>

### Atypical HUS affects BOTH adults and children

• The onset of atypical HUS occurs as frequently during adulthood as during childhood<sup>7</sup>

To learn more about the aHUS Registry or to enrol your patients, contact your Alexion Representative or e-mail aHUS-Registry@incresearch.com

#### References:

- Langman C, et al. Systemic Multi-Organ Complications in Atypical Hemolytic Uremic Syndrome (aHUS): Retrospective Study in a Medical Practice Setting. Poster #049
  presented at: 17th Congress of the European Hematology Association June 14–17, 2012; Amsterdam, Netherlands.
- Laurence J. Haller H. Mannucci PM. et al. Clin Adv Hematol Oncol. 2016;14 Suppl 11(11):2-15.
- Consister, J. J. Construction, Manual Contractor Control of Cont
- 6. George JN, Nester CM. N Engl J Med. 2014;371(19):1847-1848.





<sup>1.</sup> Geary DF, Schaefer F. The Netherlands: Springer Berlin Heidelberg; 2017.

<sup>2.</sup> Hoffman R. Elsevier Health Sciences; 2017.